Unimed Pharma

Unimed Pharma

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Unimed Pharma is a well-established, private Slovak company focused on the ophthalmic sector, operating as a manufacturer and marketer of over-the-counter (OTC) eye care products and dietary supplements. It leverages its own R&D and quality control to produce a portfolio aimed at conditions like dry eye, conjunctivitis, and general eye health support, utilizing specialized packaging like the Novelia® system for preservative-free formulations. The company appears to be revenue-generating with a commercial-stage portfolio, targeting the Central European market through collaborations with eye doctors, clinics, and pharmacies. Its strategy is built on decades of experience, proven quality, and addressing common eye health needs rather than novel drug development for neurological disorders as previously indicated.

OphthalmologyEye Health

Technology Platform

Formulation expertise and specialized drug delivery for ophthalmic products, including preservative-free multi-dose packaging (Novelia® system).

Opportunities

Growing global demand for OTC eye care, especially preservative-free formulations, driven by an aging population and increased digital device use.
Rising awareness of nutritional supplements for eye health and the 'myopia epidemic' provides additional market segments for portfolio expansion.

Risk Factors

High competition from large multinational pharmaceutical companies in the consumer eye health space.
Geographic concentration in Central Europe exposes the company to regional market risks.
Reliance on incremental product innovation rather than novel drug pipelines for growth.

Competitive Landscape

Operates in the competitive OTC ophthalmology market against giants like Alcon, Bausch + Lomb, and Thea Pharmaceutical. Competes on the basis of regional trust, specialized preservative-free packaging, and direct HCP relationships rather than blockbuster novel drugs.